Vapotherm to Report Second Quarter 2020 Financial Results
July 21 2020 - 4:01PM
Business Wire
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a
global medical technology company focused on the development and
commercialization of Vapotherm’s proprietary high velocity therapy,
which is used to treat patients of all ages suffering from
respiratory distress, today announced that it will release
financial results for the second quarter of 2020 after the close of
trading on Tuesday, August 4, 2020. Vapotherm’s management team
will host a conference call beginning at 4:30 p.m. ET to discuss
the financial results and recent business developments.
To listen to the conference call on your telephone, please dial
(833) 714-0922 for U.S. callers, or +1 (778) 560-2684 for
international callers, approximately ten minutes prior to the start
time and reference conference code 8283367. To listen to a live
webcast, please visit the Investors section of the Vapotherm
website at:
http://investors.vapotherm.com/events-and-presentations/events. The
webcast replay will be available on the Vapotherm website for 90
days following completion of the call. A replay of this conference
call will be available by telephone through August 11, 2020 by
dialing (800) 585-8367 in the U.S. or (416) 621-4642 outside of the
U.S. The replay access code is 8283367.
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded
developer and manufacturer of advanced respiratory technology based
in Exeter, New Hampshire, USA. The company develops innovative,
comfortable, non-invasive technologies for respiratory support of
patients with chronic or acute breathing disorders. Over 2.2
million patients have been treated with Vapotherm high velocity
therapy. For more information, visit www.vapotherm.com.
Vapotherm high velocity therapy is mask-free noninvasive
ventilatory support and is and a front-line tool for relieving
respiratory distress—including hypercapnia, hypoxemia, and dyspnea.
It allows for the fast, safe treatment of undifferentiated
respiratory distress with one user-friendly tool. The Precision
Flow system’s mask-free interface delivers optimally conditioned
breathing gases, making it comfortable for patients and reducing
the risks and care complexities associated with mask therapies.
While being treated, patients can talk, eat, drink and take oral
medication.
Website Information Vapotherm routinely posts important
information for investors on the Investor Relations section of its
website, http://investors.vapotherm.com/. Vapotherm intends to use
this website as a means of disclosing material, non-public
information and for complying with Vapotherm’s disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the Investor Relations section of Vapotherm’s website, in
addition to following Vapotherm’s press releases, Securities and
Exchange Commission filings, public conference calls, presentations
and webcasts. The information contained on, or that may be accessed
through, Vapotherm’s website is not incorporated by reference into,
and is not a part of, this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200721005581/en/
Investor Relations Contact: Mark Klausner or Mike Vallie,
Westwicke, an ICR Company, ir@vtherm.com, +1-(603)-658-0011
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Apr 2023 to Apr 2024